| Apr 7 |
Big Rock Partners Acquisition Corp. Clarifies Procedure for Stockholder Conversions and Urges Stockholders To Vote "For" Extension Amendment Proposal
|
| Apr 6 |
NeuroRx Announces Zyesami™ (Aviptadil) Has Been Selected for Inclusion in NIH-Sponsored Global Clinical Trial to Include Aviptadil and Remdesivir
|
| Mar 29 |
63 Biggest Movers From Friday
|
| Mar 29 |
NeuroRx Announces ZYESAMI™ (aviptadil, RLF-100) Met the Primary Endpoint of Its Phase 2b/3 Clinical Trial and Also Demonstrated a Meaningful Benefit in Survival from Critical COVID-19
|
| Mar 26 |
NeuroRx Announces Completion of Data Analysis in Phase 2b/3 Clinical Trial of ZYESAMI™ for the Treatment of COVID-19 Respiratory Failure
|
| Mar 15 |
Neurorx, Inc. and Big Rock Partners Acquisition Corp. Announce Committed $10 Million Pipe to Support Proposed Business Combination
|
| Mar 12 |
SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, BRPA, and KTYB Shareholders About Its Ongoing Investigations
|
| Mar 9 |
NeuroRX and TFF Pharmaceuticals Announce Entering Into Feasibility Collaboration
|
| Feb 26 |
SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations
|
| Feb 23 |
NeuroRx Announces that ZYESAMI™ (Aviptadil) has Successfully Demonstrated 10-Day Accelerated Recovery from Respiratory Failure in Critically Ill Patients with Covid-19 Treated with High Flow Nasal Oxygen at 28-Day Interim Endpoint
|
| Feb 19 |
SHAREHOLDER ALERT: WeissLaw LLP Reminds GIX, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations
|
| Feb 12 |
SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, JWS, BRPA and KTYB Shareholders About Its Ongoing Investigations
|
| Feb 9 |
Mid-Day Market Update: KalVista Pharmaceuticals Jumps Following Positive HAE Readout; Ekso Bionics Shares Slide
|
| Feb 9 |
70 Stocks Moving In Tuesday's Mid-Day Session
|
| Feb 9 |
NeuroRx reports Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ (aviptadil) in Reducing Hospital Stay among Patients with Respiratory Failure due to Critical COVID-19
|
| Feb 9 |
NeuroRx and Relief Therapeutics Report Initial Phase 2b/3 Study Results Demonstrating Significant Benefit of ZYESAMI™ in Reducing Hospital Stay Among Patients with Respiratory Failure due to Critical COVID-19
|
| Feb 7 |
Lifshitz Law Firm, P.C. Announces Investigation of BRPA, CGRO, GXGX, HEC, FSRV, LCY, STPK, TPGY and VSPR
|
| Feb 5 |
SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, JWS, and BRPA Shareholders About Its Ongoing Investigations
|
| Jan 29 |
SHAREHOLDER ALERT: WeissLaw LLP Reminds JWS, BRPA, and UROV Shareholders About Its Ongoing Investigations
|
| Jan 22 |
SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, JWS, BRPA, and ZAGG Shareholders About Its Ongoing Investigations
|
| Jan 14 |
SHAREHOLDER ALERT: WeissLaw LLP Reminds STPK, FIII, JWS and BRPA Shareholders About Its Ongoing Investigations
|
| Jan 11 |
NeuroRx, Relief, and Quantum Leap announce the inclusion of ZYESAMI™ (RLF-100™: aviptadil) in the I-SPY COVID-19 Trial
|
| Jan 7 |
SHAREHOLDER ALERT: WeissLaw LLP Reminds FIII, JWS, BRPA, and CGIX Shareholders About Its Ongoing Investigations
|
| Dec 31 |
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Big Rock Partners Acquisition Corp. - BRPA
|
| Dec 30 |
NeuroRx and Relief Conclude Enrollment in their Phase 2b/3 Trial of RLF-100™ for Critical COVID-19 with Respiratory Failure
|
